Uveal melanoma (UM) is the most common type of cancer inside the eyes of adults. Almost half
of all patients diagnosed with UM will eventually develop metastases. Once metastases occur,
the median patient survival is short.
In this trial, we will test if treatment with Melatonin after primary tumor diagnosis can
prevent or delay the development of metastases. 100 patients diagnosed with primary UM will
be randomized to either treatment with Melatonin tablets (20 mg at night), or to a control
group. Both groups will be followed for 5 years. At 5 years, the number of patients that have
developed metastases in the Melatonin and control groups will be compared (primary outcome
measure).
Phase:
Phase 3
Details
Lead Sponsor:
Gustav Stalhammar
Collaborators:
Karolinska Trial Alliance Swedish Cancer Society The Swedish Eye Foundation (Ögonfonden) The Swedish Society of Medicine